SE8803486D0 - Dosage form for treating cardiovascular diseases - Google Patents

Dosage form for treating cardiovascular diseases

Info

Publication number
SE8803486D0
SE8803486D0 SE8803486A SE8803486A SE8803486D0 SE 8803486 D0 SE8803486 D0 SE 8803486D0 SE 8803486 A SE8803486 A SE 8803486A SE 8803486 A SE8803486 A SE 8803486A SE 8803486 D0 SE8803486 D0 SE 8803486D0
Authority
SE
Sweden
Prior art keywords
dosage form
cardiovascular diseases
treating cardiovascular
composition
treating
Prior art date
Application number
SE8803486A
Other languages
English (en)
Other versions
SE503471C2 (sv
SE8803486L (sv
Inventor
A D Ayer
D R Swanson
A L Kuczinsky
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of SE8803486D0 publication Critical patent/SE8803486D0/sv
Publication of SE8803486L publication Critical patent/SE8803486L/sv
Publication of SE503471C2 publication Critical patent/SE503471C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE8803486A 1987-10-02 1988-09-30 Osmotisk dosform innehållande isradipin SE503471C2 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/104,006 US4816263A (en) 1987-10-02 1987-10-02 Dosage form for treating cardiovascular diseases comprising isradipine

Publications (3)

Publication Number Publication Date
SE8803486D0 true SE8803486D0 (sv) 1988-09-30
SE8803486L SE8803486L (sv) 1989-04-03
SE503471C2 SE503471C2 (sv) 1996-06-24

Family

ID=22298196

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8803486A SE503471C2 (sv) 1987-10-02 1988-09-30 Osmotisk dosform innehållande isradipin

Country Status (22)

Country Link
US (1) US4816263A (sv)
JP (1) JP2590235B2 (sv)
KR (1) KR950010151B1 (sv)
AT (1) AT402689B (sv)
AU (1) AU615215B2 (sv)
BE (1) BE1001101A5 (sv)
CA (1) CA1317550C (sv)
CH (1) CH677609A5 (sv)
DE (1) DE3833282C2 (sv)
DK (1) DK175564B1 (sv)
ES (1) ES2011120A6 (sv)
FI (1) FI92554C (sv)
FR (1) FR2622798B1 (sv)
GB (1) GB2210266B (sv)
IE (1) IE61862B1 (sv)
IT (1) IT1234215B (sv)
LU (1) LU87351A1 (sv)
NL (1) NL194748C (sv)
NO (1) NO176466C (sv)
PT (1) PT88618B (sv)
SE (1) SE503471C2 (sv)
ZA (1) ZA887362B (sv)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
WO2002100392A1 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
EP1412324A4 (en) * 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
AU2003297909A1 (en) * 2002-12-11 2004-06-30 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
WO2004089289A2 (en) * 2003-03-31 2004-10-21 Xenoport, Inc. Treating or preventing hot flashes using prodrugs of gaba analogs
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
BRPI0413756A (pt) * 2003-08-20 2006-10-31 Xenoport Inc composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica
JP2007505149A (ja) * 2003-09-11 2007-03-08 ゼノポート，インコーポレイティド ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防
CN1871021B (zh) * 2003-09-17 2010-07-28 什诺波特有限公司 用gaba类似物的前药治疗或预防多动腿综合征
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
ZA200800311B (en) * 2005-06-20 2009-04-29 Xenoport Inc Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
CA2578626C (en) 2005-06-27 2011-07-19 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
MX2008014794A (es) 2006-05-26 2009-04-08 Pharmacofore Inc Liberacion controlada de opioides fenolicos.
US7585996B2 (en) * 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
JP2010512314A (ja) * 2006-12-08 2010-04-22 ゼノポート，インコーポレーテッド 疾患を治療するためのｇａｂａアナログのプロドラッグの使用
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2011028234A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
CN103228142A (zh) 2010-09-28 2013-07-31 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
CN102349880B (zh) * 2011-10-12 2015-07-22 合肥华方医药科技有限公司 伊拉地平控释片及其制备方法
CN105030726A (zh) * 2015-08-30 2015-11-11 四川百利药业有限责任公司 一种伊拉地平胶囊的制备方法
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
US9808452B2 (en) 2015-10-01 2017-11-07 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
JP7234130B2 (ja) 2017-03-17 2023-03-07 エリージウム セラピューティクス， インコーポレイテッド 過剰摂取および乱用に対して抵抗性のポリサブユニットオピオイドプロドラッグ

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB2181053B (en) * 1985-10-01 1990-05-23 Sandoz Ltd Pharmaceutical formulations with controlled release of the active substance
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
AU2152888A (en) * 1987-08-25 1989-03-02 Cerra Metal Works Pty. Ltd. Masonry tie
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine

Also Published As

Publication number Publication date
GB2210266A (en) 1989-06-07
LU87351A1 (fr) 1989-04-06
SE503471C2 (sv) 1996-06-24
FI884526A0 (sv) 1988-09-30
NO884259D0 (no) 1988-09-27
DK175564B1 (da) 2004-12-06
NO176466B (no) 1995-01-02
FR2622798A1 (fr) 1989-05-12
US4816263A (en) 1989-03-28
PT88618A (pt) 1989-07-31
DK545088D0 (da) 1988-09-29
FI92554C (sv) 1994-12-12
AU2293888A (en) 1989-04-06
SE8803486L (sv) 1989-04-03
ES2011120A6 (es) 1989-12-16
FR2622798B1 (fr) 1993-10-15
CH677609A5 (sv) 1991-06-14
AU615215B2 (en) 1991-09-26
NL8802401A (nl) 1989-05-01
DK545088A (da) 1989-04-03
JP2590235B2 (ja) 1997-03-12
ATA242288A (de) 1996-12-15
FI884526A (sv) 1989-04-03
CA1317550C (en) 1993-05-11
NO884259L (no) 1989-04-03
ZA887362B (en) 1989-06-28
BE1001101A5 (fr) 1989-07-11
IE61862B1 (en) 1994-11-30
AT402689B (de) 1997-07-25
DE3833282A1 (de) 1989-04-20
IT1234215B (it) 1992-05-06
IE882960L (en) 1989-04-02
GB8822852D0 (en) 1988-11-02
DE3833282C2 (de) 1997-02-13
IT8867880A0 (it) 1988-09-30
PT88618B (pt) 1993-07-30
JPH01113316A (ja) 1989-05-02
GB2210266B (en) 1991-07-24
KR890006218A (ko) 1989-06-12
KR950010151B1 (ko) 1995-09-11
NL194748C (nl) 2003-02-04
NO176466C (no) 1995-04-12
FI92554B (sv) 1994-08-31
NL194748B (nl) 2002-10-01

Similar Documents

Publication Publication Date Title
SE8803486D0 (sv) Dosage form for treating cardiovascular diseases
IT8219730A0 (it) Derivati 5-amminometil-ossazolidinici, procedimento per la loro preparazione, e loro applicazione in terapia.
SE8504720D0 (sv) New drug preparation
IT7821872A0 (it) Derivati d'acetammide impiegabili segnatamente in terapia, eprocedimento per produrli.
NO903898D0 (no) Fremgangsmaate for igjenplugging av en sone i en broenn.
DE3869214D1 (de) Nadelloser injektor, insbesondere fuer die zahnmedizinische anwendung.
IT1230182B (it) Metodo ed apparato per riparare o fabbricare un oggetto.avente un supporto ed una sporgenza solidali
ES2019632B3 (es) Forma de dosificacion del verapamil
MX9203725A (es) Composiciones farmaceuticas que comprenden una calcitonina y un glicirrizinato como aumentador de absorcion.
DE68919172D1 (de) MOSFET und dessen Herstellungsverfahren.
DE68922988D1 (de) Einspritzpresse und deren giessverfahren.
NO900027D0 (no) Dobbeltdiffusoer med tilbakespylingsstempler.
KR900007816A (ko) 사이클로프로필-치환된 아졸릴메틸카비놀, 이의 제조방법 및 약제로서의 이의 용도
FI821324A0 (fi) Oxazolderivat
DE69104054D1 (de) Melatoninderivat mit therapeutischer aktivität, das in der dermatologie anwendbar ist.
DE58903109D1 (de) Doppel-einlauftisch.
SE8204871L (sv) Farmaceutiska preparat, innefattande humant proinsulin
IT1153062B (it) Derivati benzilidenici, loro preparazione e loro applicazione in terapia
IT8123488A0 (it) Metaboliti, loro preparazione eloro impiego in terapeutica.
SE8802040D0 (sv) New use
IT1224250B (it) Associzione del depiprazolo con la morfina
GR3015373T3 (en) 2-Halogen-substituted N-indolyl sulfonic-acid amides, process for their preparation and their pharmaceutical use.
ZA864717B (en) Terguride as a geriatric agent
KR900012622A (ko) 피부질환치료 조성물
IT8220819A0 (it) Derivati diossazabiciclici,loro procedimento di preparazione e loro applicazione in terapia.

Legal Events

Date Code Title Description
NUG Patent has lapsed